Coherus Oncology Posts -153.12% ROIC Versus 11.27% WACC
Coherus Oncology reported a negative ROIC of -153.12% against a WACC of 11.27%, reflecting severe capital inefficiency that places its ROIC/WACC ratio at -13.59. In contrast, Atara Biotherapeutics achieved a 222.66% ROIC with a 5.98% WACC, demonstrating robust return generation.
1. Coherus Oncology’s Capital Inefficiency
Coherus Oncology generated a ROIC of -153.12% in its latest analysis while its WACC stood at 11.27%, resulting in a ROIC/WACC ratio of -13.59. This stark imbalance indicates the company is not recouping its cost of capital and highlights significant inefficiencies in its investment returns.
2. Comparison with Biopharma Peers
Among peers, Atara Biotherapeutics achieved a ROIC of 222.66% with a WACC of 5.98%, reflecting strong profitability and capital utilization. Other companies like FibroGen, MacroGenics, CytomX Therapeutics and Blueprint Medicines also reported negative ROICs but none as severe as Coherus, underscoring Coherus’s relative underperformance.
3. Strategic and Investor Implications
The negative ROIC to WACC ratio serves as a warning sign for investors, suggesting the need for Coherus to optimize its pipeline investments or restructure capital allocation. Without improvements in operational efficiency or higher-margin product launches, the company may continue to struggle to deliver value for shareholders.